Grant: Idea to Innovation
Ryerson University
$20,000.00
Lab2Market NSERC I2I Market Assessment of positive pombe: engineering anti-depressant molecules in fission yeast
FY 2021-22
Summary
We are developing a synthetic biology platform for biologically important molecule production in fission yeast (Schizosaccharomyces pombe). This Lab2Market I2I Market Assessment program allows us to assess our technology and offering within the current market. We examine our primary research/technology development, expanding on a general customer-based survey in the Lab2Market Mitacs program. Our initial molecule of interest is psilocybin. Psilocybin is a potential compound to treat depression, addiction, and anxiety. It would be an alternative to other pharmaceutical drugs. Psilocybin is related to naturally occurring molecules found in cells, and results from a chemical conversion in Psylocibe mushrooms. However, extracting and purifying psilocybin from mushrooms leads to variable products, and large-scale extraction is not possible. Chemical synthesis is possible but expensive. We will use enzymes from the mushroom and express them in fission yeast cells. These yeast cultures provide an opportunity for consistent and high- yield synthesis from starting media. Long-term, we eliminate the time, space, and labor-intensive method of harvesting mushrooms, and the cost-intensive method of psilocybin chemical synthesis from expensive starting materials. In the future, we expect that this will allow us to generate other related compounds effective in an optimized synthetic biology platform, and with linked market considerations.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
571247-2022
Name nom
Sabatinos, Sarah
Department département
Chemistry and Biology
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2022
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
100
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Agriculture and primary food production
Area of application fr
Agriculture et produits alimentaires primaires
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Installment
inst:1
Partie
1
Nb partie
1
Application title
Lab2Market NSERC I2I Market Assessment of positive pombe: engineering anti-depressant molecules in fission yeast
Keyword
NSERC
Application summary
We are developing a synthetic biology platform for biologically important molecule production in fission yeast (Schizosaccharomyces pombe). This Lab2Market I2I Market Assessment program allows us to assess our technology and offering within the current market. We examine our primary research/technology development, expanding on a general customer-based survey in the Lab2Market Mitacs program. Our initial molecule of interest is psilocybin. Psilocybin is a potential compound to treat depression, addiction, and anxiety. It would be an alternative to other pharmaceutical drugs. Psilocybin is related to naturally occurring molecules found in cells, and results from a chemical conversion in Psylocibe mushrooms. However, extracting and purifying psilocybin from mushrooms leads to variable products, and large-scale extraction is not possible. Chemical synthesis is possible but expensive. We will use enzymes from the mushroom and express them in fission yeast cells. These yeast cultures provide an opportunity for consistent and high- yield synthesis from starting media. Long-term, we eliminate the time, space, and labor-intensive method of harvesting mushrooms, and the cost-intensive method of psilocybin chemical synthesis from expensive starting materials. In the future, we expect that this will allow us to generate other related compounds effective in an optimized synthetic biology platform, and with linked market considerations.